We are live on ! Find out more
AVM

Arch Venture Management Portfolio holdings

AUM $677M
1-Year Est. Return 322.07%
This Fund
S&P 500
This Quarter Est. Return
-14.48%
1 Year Est. Return
+322.07%
3 Year Est. Return
+208.96%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$91.4M
AUM Growth
-$5.22M
Cap. Flow
+$23.5M
Cap. Flow %
25.69%
Top 10 Hldgs %
100%
Holding
5
New
1
Increased
–
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$36.4M

Top Sells

Rank Stock Value
1
KURA icon
Kura Oncology
KURA
+$8.01M
2
FATE icon
Fate Therapeutics
FATE
+$4.92M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRS
1
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$40M 43.8%
+385,505
New +$36.4M
RUBY
2
DELISTED
Rubius Therapeutics, Inc
RUBY
$20.6M 22.5%
2,618,351
– –
KURA icon
3
Kura Oncology
KURA
$916M
$13.7M 15.05%
906,307
-450,000
-33% -$8.01M
FATE icon
4
Fate Therapeutics
FATE
$290M
$11.1M 12.18%
716,392
-256,798
-26% -$4.92M
CHMA
5
DELISTED
Chiasma, Inc. Common Stock
CHMA
$5.92M 6.48%
1,196,776
– –

Similar funds

NI
Noked Israel Ramat Hasharon, Israel $677M AUM 69.37% 1-Year Est. Return
MMPW
Mitchell McLeod Pugh & Williams Mobile, Alabama $678M AUM 23.02% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
NCM
Noesis Capital Mangement Boca Raton, Florida $676M AUM 34.17% 1-Year Est. Return
TWM
Topsail Wealth Management Charlotte, North Carolina $678M AUM 13.87% 1-Year Est. Return
DLIC
Daido Life Insurance Company Osaka, Japan $678M AUM 16.09% 1-Year Est. Return
REAM
Ripple Effect Asset Management New York $679M AUM 81.6% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Arch Venture Management's Q3 2019 Portfolio in Review

As of Q3 2019, Arch Venture Management held 5 positions worth $91.4M, down 5.4% from $96.6M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Arch Venture Management deployed $23.5M of net new capital in Q3 2019, opening 1 new position. Its largest new stake was Syros Pharmaceuticals, Inc. Common Stock: 385,505 shares worth $40M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Kura Oncology, an estimated $8.01M trimmed.

  • Arch Venture Management's largest Q3 2019 buy was Syros Pharmaceuticals, Inc. Common Stock: 385,505 shares worth $40M.
  • Arch Venture Management's biggest Q3 2019 reduction was Kura Oncology, cutting an estimated $8.01M.
  • Arch Venture Management's ten largest holdings make up 100% of its $91.4M portfolio in Q3 2019.
  • Arch Venture Management opened 1 new position and closed 0 in Q3 2019.
  • Arch Venture Management's portfolio value fell 5.4% quarter-over-quarter to $91.4M.

Based on Arch Venture Management's 13F filing for Q3 2019, filed 12 Nov 2019.